drugset / Trial / NCT02660255

Safety and Tolerability of Cannabidiol in Subjects With Drug Resistant Epilepsy

NCT02660255

Expanded access Approved for marketing University of Nebraska Jazz Pharmaceuticals · collab

Summary

This is an observational, open-label, flexible dose study that will prospectively and longitudinally assess the effect of Cannabidiol (CBD) therapy in patients with drug-resistant epilepsies through a Physician Expanded Access Investigational New Drug protocol.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Cannabidiol Other / unclassified 100 mg/ml Oral

Indications